Search research articles
Contact Us
Filters
Showing results (101-110 of 182) with videos related to
Page
of 19
Sort By:
Cancer Immunology, Immunotherapy : CII
|
January 15, 2008
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Takuya Osada, Gabriel Chong, Robert Tansik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2010
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors
José Baselga, Andres Cervantes, Erika Martinelli, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 25, 2010
Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma
A Paiman Ghafoori, John W Nelson, Christopher G Willett, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 21, 2007
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma
Brian G Czito, Darrel P Cohen, Chris R Kelsey, et al.
Journal of the National Cancer Institute
|
July 7, 2005
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab
William L Ince, Adrian M Jubb, Scott N Holden, et al.
Anticancer Research
|
January 29, 2011
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer
Nan Soon Wong, Nishan H Fernando, Andrew B Nixon, et al.
Cancer Chemotherapy and Pharmacology
|
December 21, 2014
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors
Hope E Uronis, Jingquan Jia, Johanna C Bendell, et al.
Molecular Cancer Therapeutics
|
February 20, 2015
Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus
Yingmiao Liu, Mark D Starr, John C Brady, et al.
Journal of Surgical Oncology
|
February 8, 2012
Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Katia T Papalezova, Douglas S Tyler, Dan G Blazer, et al.
Clinical Genitourinary Cancer
|
April 2, 2014
A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma
Rhonda L Bitting, Patrick Healy, Patricia A Creel, et al.
Page
of 19
Search research articles
Search
Showing results (101-110 of 182) with videos related to
Sort By:
Page
of 19
Cancer Immunology, Immunotherapy : CII
|
January 15, 2008
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
Takuya Osada, Gabriel Chong, Robert Tansik, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2010
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors
José Baselga, Andres Cervantes, Erika Martinelli, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 25, 2010
Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma
A Paiman Ghafoori, John W Nelson, Christopher G Willett, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 21, 2007
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma
Brian G Czito, Darrel P Cohen, Chris R Kelsey, et al.
Journal of the National Cancer Institute
|
July 7, 2005
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab
William L Ince, Adrian M Jubb, Scott N Holden, et al.
Anticancer Research
|
January 29, 2011
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer
Nan Soon Wong, Nishan H Fernando, Andrew B Nixon, et al.
Cancer Chemotherapy and Pharmacology
|
December 21, 2014
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors
Hope E Uronis, Jingquan Jia, Johanna C Bendell, et al.
Molecular Cancer Therapeutics
|
February 20, 2015
Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus
Yingmiao Liu, Mark D Starr, John C Brady, et al.
Journal of Surgical Oncology
|
February 8, 2012
Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Katia T Papalezova, Douglas S Tyler, Dan G Blazer, et al.
Clinical Genitourinary Cancer
|
April 2, 2014
A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma
Rhonda L Bitting, Patrick Healy, Patricia A Creel, et al.
Page
of 19